|
 |
Kauppanimi |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Mabthera |
Argentiina, Australia, Belgia, Chile, Ecuador, Egypti, Espanja, Hollanti, Irlanti, Islanti, Iso-Britannia, Italia, Itävalta, Japani, Kolumbia, Kreikka, Kroatia, Luxemburg, Marokko, Marokko, Meksiko, New Zealand, Norja, Portugali, Puola, Ranska, Romania, Ruotsi, Saksa, Saudi-Arabia, Suomi, Sveitsi, Tanska, Tunisia, Turkki, Unkari, Venezuela, Yhdistyneet arabiemiirikunnat |
|
Novex |
Argentiina |
|
Reditux |
Chile, Marokko |
|
Rigetuxer |
Meksiko |
|
Rituxan |
Japani, Kanada, Yhdysvallat |
|
Rituximab |
New Zealand |
|
Rixathon |
Belgia, Espanja, Iso-Britannia, Ranska, Saksa, Sveitsi |
|
Truxima |
Belgia, Espanja, Iso-Britannia, Kanada, Ranska, Saksa, Yhdysvallat |
|
|
 |
 |
Viitteet : Rituximab |
|
|
tyyppi |
julkaisu |
| 2296 |
Laboratorio |
Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017 |
| 2825 |
Lehti |
Mueller C, Dietel E, Heynen S, Nalenz H, Goldbach P, Mahler H, Schmidt J, Grauschopf U, Schoenhammer K.
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials.
Int J Pharm Compound 2015 ; 19, 3: 261-267. |
| 2881 |
ilmoitus |
Jaccoulet E, Guirao S, Morand K, Astier A, Paul M.
Stabilité d'un anticorps monoclonal d'intérêt thérapeutique après reconstitution: le rituximab.
SFPO Congress 2009 |
| 3323 |
Lehti |
Paul M, Vieillard V, Jaccoulet E, Astier A.
Long-term stability of diluted solutions of the monoclonal antibody rituximab.
Int J Pharm 2012 ; 436, 1-2: 282-290. |
| 4016 |
Lehti |
Vieillard V, Paul M, Ibrahim T, Astier A.
Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bag.
Ann Pharm Fr 2017 ; 75, 6: 420-435. |
| 4040 |
Lehti |
Lamanna W.C, Heller K, Schneider D, Guerrasio R, Hampl V, Fritsch C, Schiestl M.
The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
J Oncol Pharm Practice 2017 ;25,2: 269-278 |
| 4676 |
ilmoitus |
Borišek R, Šmid I.
Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days.
EAHP Congress Vienna 2022 |
| 4708 |
Lehti |
Borišek R, Mischo A, Šmid I.
Study of the Stability of Sandoz Rituximab Biosimilar Rixathon®/Riximyo® When Subjected for up to 21 Days to Ambient Storage.
Drugs R D 2022 ; 22,3: 225–234 |
| 4740 |
Laboratorio |
MabThera 500 mg concentrate for solution for infusion. Summary of Product Characteristics Updated 07-Oct-2021
Roche Products Limited 2021 |
|
|
